Best Practices and Strategies for Luspatercept in the Treatment of LR-MDS

Thomas W. LeBlanc, MD, MA, discusses key clinical pearls for community oncologists in the treatment of anemia in patients with low-risk myelodysplastic syndromes (LR-MDS), including the importance of early and accurate diagnosis, considering newer therapies like luspatercept, monitoring hemoglobin levels, and incorporating patient-reported outcomes to tailor individualized treatment plans for better outcomes.

EP: 1.An Overview of the Treatment Landscape for Anemia Management in LR-MDS

EP: 2.Updates From COMMANDS at ASH 2024

EP: 3.The Role of Luspatercept in the Evolving Treatment Landscape of LR-MDS

EP: 4.Considerations for Treatment Sequencing in LR-MDS

EP: 5.Academic Perspectives on Health-Related Quality of Life From COMMANDS at ASH 2024

Now Viewing

EP: 6.Best Practices and Strategies for Luspatercept in the Treatment of LR-MDS

Video content above is prompted by the following:

What clinical pearls could you share with community oncologists about the treatment of anemia for patients with LR-MDS?

Recent Videos